iRhythm Technologies announced initial research findings on its Zio monitor’s post-market, real-world performance. The company presented the data on its next-generation long-term continuous monitoring (LTCM) patch ECG device at Heart Rhythm Society’s HRX 2024 meeting.
Related: ExThera Medical’s OSCAR I Study enrols first pancreatic cancer treatment patient
Zio builds on the previous-generation Zio XT with long-term, continuous cardiac monitoring for up to 14 days. It provides an end-to-end experience for patients with potential arrhythmias and demonstrates 99% patient compliance. iRhythm launched the next-generation monitor in the U.S. in September.
iRhythm also kicked off the launch of its Zio monitoring service in Austria, the Netherlands, Spain and Switzerland last month. The technology, along with the supporting Zeus AI algorithm, picked up CE mark at the start of the year.
The real-world data presented at HRX by iRhythm compared post-market performance for Zio against the previous-generation Zio XT. Zio demonstrated fewer earlier wear terminations, longer wear duration and longer analyzable time compared to Zio XT. It also delivered a greater yield of paroxysmal AFib and overall arrhythmia detection than the previous generation.
“Not all ambulatory cardiac monitoring services are the same. We first learned that in the CAMELOT study,1 where Zio XT provided greater diagnostic yield and less retesting than other monitors,” said Dr. Rod S. Passman, cardiac electrophysiologist, professor of medicine at Northwestern University and presenting author. “Now, we are seeing the impact of design enhancements on device performance, with even better wear time and analyzable time with the new device. Taken together, these advancements could contribute to better patient compliance and higher arrhythmia detection rates.”
